HANAWA Fumie 花輪書絵

Researcher Number	80535592
Affiliation (based on the past Project Information) *help	2011 – 2013: 山梨大学, 医学部附属病院, 助教
Review Section/Research Field	Principal Investigator Dermatology Except Principal Investigator Dermatology
Keywords	Principal Investigator STAT3阻害薬 / STAT3 / 腫瘍免疫 / 悪性黒色腫 / 皮膚腫瘍学 / 皮膚科学 Except Principal Investigator がん免疫 / メラノーマ / STAT3 / 癌免疫療法 … More / 皮膚腫瘍 / ワクチン / 悪性黒色腫 / 腫瘍免疫 Less

Analysis for the anti-tumor effect of STAT3 inhibitor (rR9-GRIM19) against tumor-bearing hostPrincipal Investigator
- Principal Investigator
  
  HANAWA Fumie
- Project Period (FY)
  2012 – 2013
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Dermatology
- Research Institution
  University of Yamanashi
Analyses for the establishment of the effective immunotherapy to melanoma-bearing hosts
- Principal Investigator
  
  SHIBAGAKI Naotaka
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Dermatology
- Research Institution
  University of Yamanashi

All 2013 2012 2011

All Presentation

[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-g producing potential2013
- Author(s)
  Fumie Hanawa, et al
- Organizer
  第17回日本がん免疫学会総会
- Place of Presentation
  宇部
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] IL-6 and IL-10 secreted from B16 melanoma cells initiate the differentiation of CD4+/ CD8+ T cells in cancer microenvironment: Inhibition of STAT3-signaling cascades is prerequisite to cancer immunotherapies.2013
- Author(s)
  Fumie Hanawa, Takashi Okamoto, Naotaka Shibagaki, and Shinji Shimada.
- Organizer
  International Investigative Dermatology (IID) 2013
- Place of Presentation
  Edinburgh International Conference Centre (EICC),Edinburgh, England
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-gamma-producing potential.2013
- Author(s)
  花輪書絵
- Organizer
  第１７回日本がん免疫学会総会
- Place of Presentation
  ANAクラウンプラザホテル宇部（山口県宇部市）
- Data Source
  KAKENHI-PROJECT-23591613
[Presentation] IL-6 and IL-10 secreted from B16 melanoma cells initiate the differentiation of CD4+/CD8+ T cells in cancer microenvironment2013
- Author(s)
  Fumie Hanawa, et al
- Organizer
  International Investigative Dermatology
- Place of Presentation
  Edinburgh
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-gamma-producing potential2013
- Author(s)
  花輪書絵
- Organizer
  日本癌免疫学会
- Place of Presentation
  ANAクラウンプラザホテル宇部（山口県宇部市）
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via T cell conversion of IL-10 into IL-17/IFN gamma-producing phenotypes2012
- Author(s)
  Naotaka Shibagaki,Fumie Hanawa, and Shinji Shimada.
- Organizer
  第１６回日本がん免疫学会総会
- Place of Presentation
  北海道大学　学術交流会館, Hokkaido
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] Complete B16 melanoma regression with Trp-2-specific CTL expansion is elicited by intratumoral injections of a novel STAT3 inhibitor (rR9-GRIM19) plus Tc1/Th1 inducers without melanoma specific immunotherapy2012
- Author(s)
  Fumie Hanawa, et al
- Organizer
  The 42nd Annual Meetings of the European Society for Dermatological Research
- Place of Presentation
  Italy
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via T cell conversion of IL-10 into IL-17/IFNgamma-producing phenotypes2012
- Author(s)
  Fumie Hanawa, et al
- Organizer
  第16回日本がん免疫学会総会
- Place of Presentation
  沖縄
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via both CD8+ and CD4+T cell conversion of IL-10 into IL-17/IFN-gamma-producing phenotypes2012
- Author(s)
  花輪書絵、柴垣直孝
- Organizer
  第37回日本研究皮膚科学会総会
- Place of Presentation
  那覇市
- Year and Date
  2012-12-08
- Data Source
  KAKENHI-PROJECT-23591613
[Presentation] A20 tumor regressions by rR9-GRIM19 is elicited via both CD8+ and CD4+ T cell conversion of IL-10 into IL-17/ IFN-gamma-producing phenotypes.2012
- Author(s)
  花輪書絵
- Organizer
  第３７回日本研究皮膚科学会総会
- Place of Presentation
  ロワジールホテル那覇（那覇）
- Data Source
  KAKENHI-PROJECT-23591613
[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via both CD8+ and CD4+ T cell conversion of IL-10-producing into IL-17/ IFN-gamma-producing phenotypes2012
- Author(s)
  Fumie Hanawa, Naotaka Shibagaki, Takashi Okamoto, and Shinji Shimada.
- Organizer
  The 38th Annual Meeting of the Japanese Society for Investigative Dermatology
- Place of Presentation
  ロワジールホテル那覇,Okinawa
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] Complete B16 melanoma regression with Trp2-specific CTL expansion is elicited by intratumoral injections of a novel STAT3 inhibitor (rR9-GRIM19) plus Tc1/ Th1 inducers without melanoma-specific immunotherapy2012
- Author(s)
  Fumie Hanawa, Naotaka Shibagaki, Takashi Okamoto, and Shinji Shimada.
- Organizer
  The 42nd Annual Meeting of the European Society for Dermatological Research
- Place of Presentation
  Palazzo del Casin;, Venice Lido Congress Centrevenice, Italy
- Data Source
  KAKENHI-PROJECT-24791145
[Presentation] CTL-mediated complete B16-melanoma ....2011
- Author(s)
  Fumie Hanawa, Naotaka Shibagaki, et al.
- Organizer
  第３６回日本研究皮膚科学会総会
- Place of Presentation
  京都国際会議場（京都）
- Data Source
  KAKENHI-PROJECT-23591613
[Presentation] CTL-mediated complete B16-melanoma rejection was elicited only by the combination therapy with STAT3-inhibitor plus Th1-inducer stimulations2011
- Author(s)
  花輪書絵、柴垣直孝
- Organizer
  第36回日本研究皮膚科学会総会
- Place of Presentation
  京都市
- Year and Date
  2011-12-09
- Data Source
  KAKENHI-PROJECT-23591613

1. SHIBAGAKI Naotaka (40262662)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
2. INOZUME Takashi (80334853)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

HANAWA Fumie 花輪 書絵

Research Projects

Research Products

Co-Researchers

Analysis for the anti-tumor effect of STAT3 inhibitor (rR9-GRIM19) against tumor-bearing hostPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Analyses for the establishment of the effective immunotherapy to melanoma-bearing hosts

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-g producing potential2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] IL-6 and IL-10 secreted from B16 melanoma cells initiate the differentiation of CD4+/ CD8+ T cells in cancer microenvironment: Inhibition of STAT3-signaling cascades is prerequisite to cancer immunotherapies.2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-gamma-producing potential.2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] IL-6 and IL-10 secreted from B16 melanoma cells initiate the differentiation of CD4+/CD8+ T cells in cancer microenvironment2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] IL-6 produced from B16 melanoma cells activates STAT3 in all CD4+ and CD8+ T cells with suppressing the IFN-gamma-producing potential2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via T cell conversion of IL-10 into IL-17/IFN gamma-producing phenotypes2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Complete B16 melanoma regression with Trp-2-specific CTL expansion is elicited by intratumoral injections of a novel STAT3 inhibitor (rR9-GRIM19) plus Tc1/Th1 inducers without melanoma specific immunotherapy2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via T cell conversion of IL-10 into IL-17/IFNgamma-producing phenotypes2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via both CD8+ and CD4+T cell conversion of IL-10 into IL-17/IFN-gamma-producing phenotypes2012

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

[Presentation] A20 tumor regressions by rR9-GRIM19 is elicited via both CD8+ and CD4+ T cell conversion of IL-10 into IL-17/ IFN-gamma-producing phenotypes.2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] A20 tumor regression by rR9-GRIM19 is elicited via both CD8+ and CD4+ T cell conversion of IL-10-producing into IL-17/ IFN-gamma-producing phenotypes2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Complete B16 melanoma regression with Trp2-specific CTL expansion is elicited by intratumoral injections of a novel STAT3 inhibitor (rR9-GRIM19) plus Tc1/ Th1 inducers without melanoma-specific immunotherapy2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] CTL-mediated complete B16-melanoma ....2011

Author(s)

Organizer

HANAWA Fumie 花輪書絵